Alnylam Pharmaceuticals, Inc.

Astellas US LLC

Akshay Vaishnaw

Muthiah Manoharan

Rachel E Meyers

Sayda Mahgoub Elbashir

Dinah Wen-Yee Sah

Jared Gollob

Christina Gamba-Vitalo

Saraswathy V Nochur

David A Bumcrot

Ivanka Toudjarska

Burt Adelman

Saraswathy Nochur

This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a liquid particle formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as endometrial cancer.

Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets.

Methods and compositions for prevention or treatment of RSV infection

This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer.

Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. The siRNA comprises a sense strand of ALN-RSV01 and an antisense strand of ALN-RSV01.

Methods and compositions for treating or preventing fibrotic disorders, e.g., sclerotic disorders, for example scleroderma, using CD2-binding agents, e.g., LFA-3/IgG fusion polypeptides or LFA-3-binding agents, are provided.

Method for treating or preventing sclerotic disorders using CD-2 binding agents

Methods of treating viral disorders are disclosed.

Growing community of inventors

Arlington, MA, United States of America

Akshay Vaishnaw